RxDoctor Payments Data

Juan Firnhaber-Burgos, MD

Pain Medicine · Greenville, NCNPI 1669562138

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,060 of the $11,008 with a category attached, or 82.3%. 23 manufacturers reported payments, led by Medtronic at 59.0% of the total. Reporting peaked in 2023 at $2,796 and has fallen 56.8% since, to $1,207 in 2025.

$11,008in general payments, 2019–2025

Across 279 payments — averaging $39.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Boston Scientific$1K
  • Abbott$674
  • Si-bone, Inc.$577
  • Nevro Corp.$424
  • Globus Medical$330
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$1,94818%
  • Food & beverage$9,06082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,008 in reported general payments places this provider in the 80th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$96,986
Medicare patients
367
Services billed
3,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl11$9,530
Buprenorphine22$5,270
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen12$603
Gabapentin28$446
Oxycodone Hcl23$421
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$385
Baclofen21$265
Tizanidine Hcl11$55
Trazodone Hcl11$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$248$9,53011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →